SPARC Q3 FY26 results: Rs 80.57 cr loss, going concern flag raised

Going ConcernRevenue DeclinePat NegativeExceptional ItemNegative Operating CashflowResults View source PDF Explain this filing

SPARC · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.1%Reaction day

₹138.00

prior close

₹138.50

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)+1.0%+1.1% vs market

Pharmaceuticals peers, median of 159sector+0.4%+1.7% vs sector

On the reaction day the stock moved 1.1 pts more than Nifty Microcap 250 and 1.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.8

10m

+2.5

15m

+2.4

30m

+2.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.1+1.0+1.1+0.4+1.7

Next day

-0.9+0.5-1.3+0.3-1.1

-2.2-0.0-2.2+0.0-2.2

-4.3-1.5-2.9-1.2-3.2

-3.2-2.2-1.0-1.7-1.4

-3.1-1.2-1.9-1.8-1.3

-5.3-2.4-2.9-2.5-2.8

15d

-10.8-8.8-2.0-6.9-3.9

-9.3-8.3-1.0-5.1-4.2

+7.2-3.5+10.8-3.5+10.8

+22.4+6.4+16.0+2.8+19.6

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 159Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

SPARC posted Q3 FY26 standalone revenue of Rs 8.45 cr versus Rs 14.91 cr YoY. Nine month revenue fell to Rs 25.95 cr from Rs 44.58 cr. Q3 net loss was Rs 80.57 cr (including Rs 12.36 cr exceptional charge for new labour codes) and 9M loss was Rs 208.57 cr. Company flagged going concern status citing cash losses, supported by a promoter group letter. On a positive note, the US FDA granted a tradeable Rare Pediatric Disease Priority Review Voucher linked to the approval of Sezaby.

Likely market impact

Persistent losses and going concern flag are negatives for the stock. The tradeable PRV from Sezaby is a positive and can be monetised for value.